Zhao Xue, Sun Zhigui, Li Hui, Jiang Feng, Zhou Jing, Zhang Linghua
Department of Laboratory Medicine, People's Hospital of Weifang, Weifang 266001, Shandong, China.
Department of Internal Medicine, People's Hospital of Rizhao, Rizhao 276800, Shandong, China.
Cancer Biomark. 2017 Aug 23;20(2):207-216. doi: 10.3233/CBM-170566.
Thyroid carcinoma is one of the most frequent malignant tumors of the endocrine system, which accounts for nearly 1% population in newly diagnosed carcinoma worldwide and the incidence has an increasing tendency in recent years. To explore whether miR-135a-5p could affect the proliferation, invasion and migration of thyroid carcinoma cells by targeting VCAN. The expression levels of miR-135a-5p and VCAN were detected in human thyroid carcinoma tissues and cells, para-carcinoma tissues, as well as human normal thyroid cells using RT-qPCR and Western blot. In addition, dual-luciferase reporter gene assay, MTT assay, colony formation assay, wound healing assay, Transwell assay, flow cytometry analysis and in vivo tumorigenesis assay were also conducted. The results demonstrated that miR-135a-5p was down-regulated while VCAN was up-regulated both in thyroid carcinoma tissues and cells. Furthermore, the up-regulation of miR-135a-5p inhibited cell proliferation, invasion and migration of thyroid carcinoma. Dual-luciferase reporter gene assay provided evidence indicating that miR-135a-5p targeted VCAN in thyroid carcinoma. MiR-135a-5p could inhibit cell proliferation, invasion and migration of thyroid carcinoma by targeting VCAN. MiR-135a-5p and VCAN might emerge as a target for the treatment of thyroid carcinoma.
甲状腺癌是内分泌系统最常见的恶性肿瘤之一,在全球新诊断的癌症中占近1%的人口,且近年来发病率呈上升趋势。为了探究miR-135a-5p是否可通过靶向VCAN影响甲状腺癌细胞的增殖、侵袭和迁移。采用RT-qPCR和蛋白质免疫印迹法检测人甲状腺癌组织和细胞、癌旁组织以及人正常甲状腺细胞中miR-135a-5p和VCAN的表达水平。此外,还进行了双荧光素酶报告基因检测、MTT检测、集落形成检测、伤口愈合检测、Transwell检测、流式细胞术分析和体内肿瘤发生检测。结果表明,甲状腺癌组织和细胞中miR-135a-5p表达下调而VCAN表达上调。此外,miR-135a-5p的上调抑制了甲状腺癌细胞的增殖、侵袭和迁移。双荧光素酶报告基因检测提供的证据表明,在甲状腺癌中miR-135a-5p靶向VCAN。miR-135a-5p可通过靶向VCAN抑制甲状腺癌细胞的增殖、侵袭和迁移。miR-135a-5p和VCAN可能成为甲状腺癌治疗的靶点。